Literature DB >> 20308603

Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.

Regan H Royer1, Jill Koshiol, Therese R Giambarresi, Linda G Vasquez, Ruth M Pfeiffer, Mary L McMaster.   

Abstract

Familial aggregation of Waldenström macroglobulinemia (WM) and related B-cell disorders (BCDs) suggests a role for genetic factors, but few data address environmental influences. We designed a questionnaire-based study to examine clinical and environmental factors in a cohort of WM families with various patterns of case aggregation. We analyzed data on 103 WM patients and 272 unaffected relatives from 35 multiple-case WM and 46 mixed WM/BCD kindred and 28 nonfamilial (sporadic) WM patients, using logistic regression models with generalized estimating equations to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for association. In this study population, the WM disease process appeared similar among patients regardless of family history. Familial WM patients were more likely than unaffected relatives to report a history of autoimmune disease (OR, 2.27; 95% CI = 1.21-4.28) and infections (OR, 2.13; 95% CI = 1.25-3.64). Familial WM patients were also more likely to report exposure to farming (OR, 2.70; 95% CI = 1.34-5.42), pesticides (OR, 2.83; 95% CI = 1.56-5.11), wood dust (OR, 2.86; 95% CI = 1.54-5.33), and organic solvents (multiple-case WM OR, 4.21; 95% CI = 1.69-10.51) compared with unaffected family members. These data provide clues to both genetic and environmental factors that may influence development of WM. Well-designed case-control studies are needed to confirm these findings.

Entities:  

Mesh:

Year:  2010        PMID: 20308603      PMCID: PMC2881498          DOI: 10.1182/blood-2009-10-247973

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Familial Waldenstrom's macroglobulinemia.

Authors:  Mary L McMaster
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

2.  Waldenström's macroglobulinemia in monozygotic twins.

Authors:  J M Fine; J Y Muller; D Rochu; M Marneux; N C Gorin; A Fine; P Lambin
Journal:  Acta Med Scand       Date:  1986

3.  Waldenström's macroglobulinaemia in a bird breeder: a case history with pulmonary involvement and antibody activity of the monoclonal IgM to canary's droppings.

Authors:  J M James; J C Brouet; E Orvoenfrija; F Capron; J Brechot; F Danon; J Diebold; J Rochemaure; R Zittoun
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

4.  Waldenström's macroglobulinaemia: three cases in shoe repairers.

Authors:  L M Williamson; M Greaves; J R Worters; C C Harling; J R Waters
Journal:  BMJ       Date:  1989-02-25

5.  Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenström's macroglobulinemia.

Authors:  J M Fine; P Lambin; M Massari; P Leroux
Journal:  Acta Med Scand       Date:  1982-05

6.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

8.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2008-08-13       Impact factor: 22.113

9.  Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers.

Authors:  Nilanjan Chatterjee; Patricia Hartge; James R Cerhan; Wendy Cozen; Scott Davis; Naoko Ishibe; Joanne Colt; Lynn Goldin; Richard K Severson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-09       Impact factor: 4.254

10.  Waldenström's macroglobulinemia and autoimmune disease in a family.

Authors:  W A Blattner; J E Garber; D L Mann; E A McKeen; R Henson; D B McGuire; W B Fisher; A W Bauman; L R Goldin; J F Fraumeni
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

View more
  12 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 2.  Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Ingemar Turesson; Magnus Björkholm; Ola Landgren
Journal:  Acta Haematol       Date:  2012-02-03       Impact factor: 2.195

Review 3.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 4.  What causes Waldenström's macroglobulinemia: genetic or immune-related factors, or a combination?

Authors:  Sigurdur Y Kristinsson; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-02

5.  Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Authors:  Akio Saito; Atsushi Isoda; Masaru Kojima; Akihiko Yokohama; Yutaka Tsukune; Makoto Sasaki; Shigeki Ito; Akihiro Ohtsu; Michiaki Koike; Kayoko Murayama; Keiichi Moriya; Hideto Tamura; Morio Matsumoto; Hirotaka Nakahashi; Sakae Tanosaki; Tohru Sakura; Toshihide Kawamura; Tomomi Miyanaga; Naoya Nakamura; Hirokazu Murakami; Hiroshi Handa; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2017-07-07       Impact factor: 2.490

Review 6.  The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.

Authors:  Abdullah Mohammad Khan
Journal:  J Pers Med       Date:  2022-04-22

Review 7.  Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions.

Authors:  Elisabet E Manasanch; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-07

8.  Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Claire M Vajdic; Ola Landgren; Mary L McMaster; Susan L Slager; Angela Brooks-Wilson; Alex Smith; Anthony Staines; Ahmet Dogan; Stephen M Ansell; Joshua N Sampson; Lindsay M Morton; Martha S Linet
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

9.  Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.

Authors:  Hemalatha Kuppusamy; Helga M Ogmundsdottir; Eva Baigorri; Amanda Warkentin; Hlif Steingrimsdottir; Vilhelmina Haraldsdottir; Michael J Mant; John Mackey; James B Johnston; Sophia Adamia; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

Review 10.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.